Bacteriological and clinical studies in the pediatric field have been performed on biapenem (L-627), a newly-developed carbapenem antibiotic, and the following results were obtained.
1. In the pharmacokinetic study, the plasma concentration of L-627 showed dose-dependant change: C
max was 14.6μg/ml and AUC was 15.4μg·hr/ml with the administration of 6mg/kg, while C
max was 49.2μg/ml and AUC was 60.1μg·hr/ml with the administration of 12mg/kg. After the administration of 6mg/kg, the urinary concentration reached maximum within 2 hours and the cumulative urinary excretion rate in the first 6 hours was 49.4%.
2. Antibacterial activities of L-627 against 27 strains of clinical isolates were determined. MICs of L-627 against such Gram-positive cocci as
Staphylococcus aureus,
Streptococcus pneumoniae and
Streptococcus pyogenes were sufficiently low, and those against such Gram-negative rods as
Haemophilus influenzae,
Escherichia coli and
Bordetella pertussis were satisfactory and as low as those of imipenem or ceftazidime.
3. Clinical efficacies of L-627 were evaluated in 36 cases of bacterial infections. The overall efficacy rate was 100%, and excellent responses in 26 cases and good in 10 cases were obtained. As for bacteriological efficacies, all strains except 1 of
B. pertussis were eradicated and a high eradication rate of 96.6% was obtained.
4. No side effects were observed in 37 evaluated cases. As abnormal laboratory test results, eosinophilia was noted in 2 cases (5.4%), but they returned to normal values rapidly after the drug was discontinued.
From these results, it has been concluded that L-627 is a safe and effective drug to be used in treatment of pediatric infectious diseases.
View full abstract